What Analysts Say about the Royalty Pharma plc (RPRX) Stock

0
4

Royalty Pharma plc (NASDAQ:RPRX) saw a downside of -0.23% to close Tuesday at $38.26 after subtracting -$0.09 on the day. The 5-day average trading volume is 1,414,360 shares of the company’s common stock. It has gained $39.10 in the past week and touched a new high 1 time within the past 5 days. An average of 1,320,225 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,469,406.

RPRX’s 1-month performance is -3.38% or -$1.18 on its low of $37.70 reached on 01/24/23. The company’s shares have touched a 52-week low of $36.15 and high of $44.75, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, RPRX has lost -3.19% or -$1.26 and has reached a new high 1 time. However, the current price is down -14.50% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Insider Transactions

RPRX stock investors last saw insider trading activity on Dec 09.RIGGS RORY B (Director) most recently sold 19,990 shares at $42.07 per share on Dec 09. This transaction cost the insider $840,939. Director, Giuliani Mario Germano, sold 84,302 shares at a price of $43.15 on Dec 05. Then, on Dec 02, Director Giuliani Mario Germano sold 197,766 shares at a price of $43.98 per share. This transaction amounted to $8,697,412.

Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.30 while the price-to-book (PB) in the most recent quarter is 2.73, with the price to cash flow ratio at 295.92.

Royalty Pharma plc’s quick ratio for the period ended June 29 was 2.10, with the current ratio over the same period at 2.10. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.99, while the total debt to equity was 1.16. The firm’s gross profit as reported stood at $858.75 million against revenue of $2.29 billion.

Earnings Surprise

For the quarterly period ending June 29 this year, Royalty Pharma plc’s cash and short-term investments amounted to $409.35 million against total debt of $7.11 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 28.55% to $142.65 million, while revenue of $304.5 million was -113.46% off the previous quarter. Analysts expected RPRX to announce $0.78 per share in earnings in its latest quarter, but it posted $0.79, representing a 1.30% surprise. EBITDA for the quarter stood at more than $197.55 million. RPRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.26 billion, with total debt at $7.11 billion. Shareholders hold equity totaling $607.22 million.

Let’s look briefly at Royalty Pharma plc (RPRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 32.97% to suggest the stock is trending Neutral, with historical volatility in this time period at 8.96%.

The stock’s 5-day moving average is $38.32, reflecting a -1.70% or -$0.66 change from its current price. RPRX is currently trading -2.37% above its 20-day SMA, -8.58% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -11.09% and SMA200 by-5.25%.

Stochastic %K and %D was 26.04% and 23.20% and the average true range (ATR) pointed at 0.66. The RSI (14) points at 34.40%, while the 14-day stochastic is at 29.32% with the period’s ATR at 0.70. The stock’s 9-day MACD Oscillator is pointing at -0.40 and -0.46 on the 14-day charts.

LEAVE A REPLY

Please enter your comment!
Please enter your name here